Satchi-Fainaro Ronit 4

What Happened

• Ronit Satchi-Fainaro, a director of Teva Pharmaceutical Industries Ltd (TEVA), received a grant of 7,242 restricted share units (RSUs) on May 28, 2026. The award is reported as an acquisition-type derivative (code A) with a $0 per-share purchase price (no cash exchanged at grant).

Key Details

• Transaction date: May 28, 2026; Form 4 filed June 1, 2026.
• Grant: 7,242 restricted share units at $0.00 (derivative award).
• Vesting: RSUs vest on May 28, 2027 (per footnote F2).
• RSU terms: Each restricted share unit is a contingent right to receive one ordinary share or, at the committee's option, the cash value of one ordinary share (footnote F1).
• ADS note: Ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share (footnote F3).
• Shares owned after transaction: Not specified in this filing.
• Filing timeliness: Form 4 filed June 1, 2026; the filing does not flag a late report in the document.

Context

• This was a compensation award, not an open-market purchase or sale. RSU grants are common for directors and typically vest over time; they do not by themselves signal an immediate buy/sell decision. The economic value will materialize if/when the RSUs vest and are settled as shares or cash.